Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108049 | 0.97 | SLC22A2 (0.48) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL25583351 | 0.94 | SLC22A2 (0.52) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL598047 | 0.94 | SLC22A2 (0.46) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL14596523 | 0.94 | SLC22A2 (0.46) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| Iodide SCHEMBL5145509 | 0.94 | SLC22A2 (0.46) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL12240437 | 0.92 | SLC22A2 (0.44) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL3354111 | 0.87 | SLC22A2 (0.46) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL1108043 | 0.86 | SLC22A2 (0.50) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 | |
| SCHEMBL5159624 | 0.85 | SLC22A2 (0.70) | SLC22A2SLC22A1SLC22A3SLC6A4 | |
| SCHEMBL12216701 | 0.84 | NOTUM (0.58) | SLC22A2SLC22A1SLC22A3SLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7500895-B2 | Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device | SEIKO EPSON CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-7273953-B2 | Process for producing arylamine | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-20060127563-A1 | Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device | SEIKO EPSON CORPORATION (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20060069287-A1 | Process for producing arylamine | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| US-20050287392-A1 | Organic electroluminescent device, method for producing the same, and electronic apparatus | SEIKO EPSON CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069287-A1 | Process for producing arylamine | TYR, AADAC, AOC2 | ACHE 1678/4885SLC22A2 3954/4885SLC22A1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.